The Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...
Read moreBiotech and pharmaceutical companies routinely spend tens of millions in clinical trials; however, p...
Read moreFor decades, the free market model of the US healthcare system has been very attractive for biotech ...
Read moreThe vast majority of products launching in the UK will be assessed by the National Institute for Hea...
Read moreDecisions regarding National Institute for Health and Care Excellence (NICE) appraisals are not made...
Read moreThe National Institute of Health and Care Excellence (NICE) has published several updates and releas...
Read moreMost pharmaceutical products hoping to launch in the UK will be assessed by NICE as a Single Technol...
Read moreSecuring a positive recommendation from the National Institute for Health and Care Excellence (NICE)...
Read moreWhen bringing a new health technology to market in England, pharmaceutical and biotech companies mus...
Read moreThe key to pricing success for any pharmaceutical product is effectively exhibiting the asset’...
Read more